Results 161 to 170 of about 362,523 (334)

552P TROPION-Lung05: Datopotamab deruxtecan (Dato-DXd) in Asian patients (pts) with previously treated non-small cell lung cancer (NSCLC) with actionable genomic alterations (AGAs) [PDF]

, 2023
M-J. Ahn, Byoung Chul Cho, Yasushi Goto, Kiyotaka Yoh, Wu‐Chou Su, Junichi Shimizu, Jin Sun Lee, Satoshi Oizumi, J.C-H. Yang, Hidetoshi Hayashi, Hong Zebger‐Gong, K. Sugiura, Lei Lan, C. Liu, Satoru Kitazono   +14 more
openalex   +1 more source

Outcomes and risk factors of hemorrhage in patients with resected brain metastases

International Journal of Cancer, EarlyView.
What's New? Brain metastases may present with hemorrhage, yet risk factors and clinical outcomes remain unclear. Based on a cohort of 880 patients with resected brain metastases, this study identified tumor volume and primary tumor histology (melanoma and non‐small cell lung cancer) as key predictors of hemorrhage.
Melisa S. Guelen, Kiarash Ferdowssian, Niklas Jung, Hava N. Celik, Andrea Dell'Orco, Semil Eminovic, Anton Früh, Majd Samman, Güliz Acker, Arend Koch, Helena Radbruch, Michael Scheel, Mike P. Wattjes, Julia Onken, Peter Vajkoczy, Nils Hecht, Jawed Nawabi, David Wasilewski   +17 more
wiley   +1 more source

Five‐year outcomes of pembrolizumab versus chemotherapy in Chinese patients with non‐small‐cell lung cancer and programmed cell death ligand 1 tumor proportion score ≥1%: KEYNOTE‐042 China study

International Journal of Cancer, EarlyView.
What's New? Global research has found that for people newly diagnosed with advanced non‐small cell lung cancer (NSCLC), the anti‐PD‐1 monoclonal antibody pembrolizumab on its own often leads to better results than traditional chemotherapy. The present report details long‐term findings of pembrolizumab therapy specifically among Chinese patients.
Yi‐Long Wu, Li Zhang, Yun Fan, JianYing Zhou, Li Zhang, Qing Zhou, Wei Li, ChengPing Hu, GongYan Chen, Xin Zhang, CaiCun Zhou, Carmen González Arenas, Zhenghong Chen, Wen Cheng Yu, Tony S. K. Mok   +14 more
wiley   +1 more source

Immunotherapy in advanced gastroesophageal cancers: A meta‐analysis of sex‐based outcomes in overall survival

International Journal of Cancer, EarlyView.
What's New? Immune checkpoint inhibitors (ICIs) improve survival in advanced gastroesophageal cancer (GEC), but their benefits may differ by sex. Little is known, however about the impact of sex‐related immune differences on ICI efficacy. In this meta‐analysis, sex‐specific outcomes of ICI therapy were evaluated in advanced GEC, encompassing both ...
Michael Masetti, Fausto Petrelli, Filippo Pietrantonio, Sylvie Lorenzen, Alberto Giovanni Leone   +4 more
wiley   +1 more source

Dual target gene therapy to EML4-ALK NSCLC by a gold nanoshell-based system [PDF]

, 2018
Achilefu, Samuel, Gu, Yueqiing, Li, Siwen, Liu, Yuxi, Rui, Yalan, Tang, Liping   +5 more
core   +2 more sources

No relevant pharmacokinetic interaction between the KRAS G12C inhibitor sotorasib and the direct oral anticoagulant rivaroxaban in healthy subjects

International Journal of Cancer, EarlyView.
What's New? Venous thromboembolism (VTE) is common in cancer patients, with direct oral anticoagulants, including rivaroxaban, recommended as first‐line therapy. However, oral anticoagulant use is limited due to the growing use of targeted therapy and concerns about drug‐drug interactions.
Esther M. Hollander, Alessandra I. G. Buma, Jenneke Leentjens, Paddy K. C. Janssen, Michel M. van den Heuvel, David M. Burger, Berber Piet, Rob ter Heine   +7 more
wiley   +1 more source

Clinical trial of safety and antitumor activity of farletuzumab ecteribulin in patients with platinum‐resistant ovarian cancer: Phase I expansion results

International Journal of Gynecology &Obstetrics, EarlyView.
Abstract Objective In the dose‐escalation part of Study 101, which included multiple tumor types, objective responses were observed in 10 of 22 patients across multiple dose levels of farletuzumab ecteribulin (FZEC). We explored the safety/antitumor activity of FZEC in patients with platinum‐resistant ovarian cancer (PROC) from the Study 101 expansion ...
Kan Yonemori, Mayu Yunokawa, Koji Matsumoto, Kazuhiro Takehara, Kosei Hasegawa, Yasuyuki Hirashima, Hidenori Kato, Hiroki Ikezawa, Yohei Otake, Wataru Yusa, Takuma Miura, Shin Nishio   +11 more
wiley   +1 more source

The Predictive Role of the 53BP1 Pathway in Advanced Non-Small-Cell Lung Cancer (NSCLC) Patients (P) Treated with First-Line Platinum-Based Chemotherapy

, 2012
Laura Bonanno, Carlota Costa, Margarita Majem, Ana Giménez‐Capitán, Ignacio Rodríguez, José Javier Sánchez, B. Massuti Sureda, Adolfo Favaretto, Massimo Rugge, Rafael Rosell   +9 more
openalex   +1 more source

A Pan‐Cancer Microenvironment Atlas Constructed by DECEPTICONx

iMetaMed, EarlyView.
DECEPTICONx builds the most comprehensive pan‐cancer TME atlas to date from > 11,000 TCGA samples using 535,665 single cells, revealing 102 immune/stromal subtypes with robust novel associations to patient outcomes, immunotherapy response, and intercellular coordination in the TME.
Yida Gu, Fulan Deng, Lianchong Gao, Zhiyu Chen, Jianping Chen, Jiale Wu, Zengqiang Xia, Zhijian Li, Fangkaikai Cheng, Jie Chen, Henry H. Y. Tong, Wantao Chen, Xiaoqing Pan, Xin Zou, Jie Hao   +14 more
wiley   +1 more source

From mechanism to phenotype: What fits in a basket trial

Epilepsia, EarlyView.
Kette D. Valente
wiley   +1 more source